Government-Owned Inventions; Availability for Licensing, 6705-6706 [05-2366]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices
6705
published as WO 2004/016155 A3 on
26 Feb 2004 (DHHS Reference No. E–
248–2001/0–PCT–02).
Licensing Contact: Michael Shmilovich;
(301) 435–5019;
shmilovm@mail.nih.gov.
Available for licensing and
commercial development is a multifocal
apparatus for delivering an agent or for
gathering information about a biological
tissue, such as optical spectroscopy for
tissue characterization (nuclear
chromatic density). The apparatus
includes a needle or catheter having a
lumen extending longitudinally at least
partially through it and a deployment
port within the distal portion of the
catheter. A plurality of extendableretractable needles are housed within
the catheter lumen, when deployed,
extend through the deployment port.
The needles may be solid or hollow and
may deliver an agent to the tissue,
include a mechanism for gathering
information about the tissue, or both.
Optical spectroscopy in a needle-based
system provides in vivo tissue
characterization without removal of
tissue for microscopic analysis, which
may be helpful during surgery or image
guided therapies to localize cancerous
tissue.
Figure 1 is a schematic diagram of one
embodiment of the apparatus in use.
The distal end of the apparatus is shown
within a neoplasm and the needles are
in a deployed state.
Figure 2 is an enlarged, longitudinal
section through the distal end of an
embodiment of the apparatus, showing
several extendable-retractable needles in
a non-deployed, or retracted, state.
In addition to licensing, the
technology is available for further
development through collaborative
research with the inventors via a
Cooperative Research and Development
Agreement (CRADA).
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Amino acid sequencing of the beginning
of the protein suggests that it is a
member of the S100 family of calcium
binding proteins. The antibody is
further described in ‘‘Characterization of
a B cell surface antigen with homology
to the S100 protein MRP8’’ by Shapiro
MA, Fitzsimmons SP, Clark KJ, Biochem
Biophys Res Commun. 1999 Sep
16;263(1):17–22 and ‘‘A novel activation
induced lymphocyte surface antigen,
90.12, is also expressed on apoptotic
cells’’ by Clark KJ, Monser M, Stein KE,
Shapiro MA, Scand J Immunol. 2000
Feb;51(2):155–63.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Monoclonal Antibody 90.12 Recognizes
a Novel B Cell Surface Antigen
Upregulated on Both Activated and
Apoptotic Lymphocytes
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
VerDate jul<14>2003
18:12 Feb 07, 2005
Jkt 205001
Methods for Analyzing High
Dimensional Data for Classifying,
Diagnosing, Prognosticating, and/or
Predicting Diseases and Other
Biological States
Marjorie A. Shapiro et al. (FDA).
DHHS Reference No. E–195–2004/0—
Research Tool.
Licensing Contact: Cristina
Thalhammer-Reyero; 301/435-4507;
thalhamc@mail.nih.gov.
Monoclonal antibody 90.12
recognizes a molecule expressed on the
surface of a subset of B lymphocytes and
on all types of blood cells. This antigen
is increased upon stimulation of B and
T lymphocytes as well as on cells
undergoing programmed cell death.
Javed Khan and Paul S. Meltzer
(NHGRI), et al.
U.S. Patent Application No. 10/133,937
filed 25 Apr 2002 (DHHS Reference
No. E–324–2001/0–US–01).
Licensing Contact: Cristina
Thalhammer-Reyero; 301/435–4507;
thalhamc@mail.nih.gov.
This invention relates to a method of
using supervised pattern recognition
methods to classifying, diagnosing,
predicting, or prognosticating various
diseases. The method includes
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
E:\FR\FM\08FEN1.SGM
08FEN1
EN08FE05.002</GPH>
Dated: February 1, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–2365 Filed 2–7–05; 8:45 am]
6706
Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices
obtaining high dimensional
experimental data, such as gene
expression profiling data, filtering the
data, reducing the dimensionality of the
data through use of one or more
methods, training a supervised pattern
recognition method, ranking individual
data points from the data, choosing
multiple data points from the data based
on the relative ranking, and using the
multiple data points to determine if an
unknown set of experimental data
indicates a diseased condition, a
predilection for a diseased condition, or
a prognosis about a diseased condition.
Artificial neural networks (ANNs) are
computer-based algorithms capable of
pattern recognition particularly suited
to making diagnoses. ANNs do not
require explicit encoding of process
knowledge in a set of rules and can be
trained from examples to recognize and
categorize complex patterns. ANNs
learn more efficiently when the data to
be input into the neural network is
preprocessed. Various ANN approaches
to the analysis of data have seen
extensive application to biomedical
problems, including those in the areas
of diagnosis and drug development.
Unsupervised neural networks are also
extensively used for the analysis of DNA
microarray data.
The technology is further described in
J. Khan et al., ‘‘Classification and
diagnostic prediction of cancers using
gene expression profiling and artificial
neural networks,’’ Nature Medicine,
7(6):673–679, June 2001.
derived from cDNA microarrays. The
ANNs were trained using as models.
The ANNs then correctly classified all
samples tested and identified the genes
most relevant to the classification. Their
study demonstrated the potential
applications of these methods for tumor
diagnosis and for the identification of
candidate targets for therapy. The
uniqueness of this method is taking
gene expression data generated by
microarrays, minimizing the genes from
the original 1000s to less than 100,
identifying which genes are the most
relevant to a classification, which gives
an immediate clue to the actual
biological processes involved, not just
surrogate markers which have no
bearing on the biology.
The technology is further described in
J. Khan et al., ‘‘Classification and
diagnostic prediction of cancers using
gene expression profiling and artificial
neural networks,’’ Nature Medicine 7(6):
673–679, June 2001.
Selections of Genes
Javed Khan and Paul S. Meltzer
(NHGRI), et al.
U.S. Patent Application No. 10/159,563
filed 31 May 2002 (DHHS Reference
No. E–324–2001/1–US–01).
Licensing Contact: Cristina
Thalhammer-Reyero; 301/435–4507;
thalhamc@mail.nih.gov.
The invention provides selections of
genes expressed in a cancer cell that
function to characterize such cancer,
and methods of using the same for
diagnosis and for targeting the therapy
of selected cancers. In particular,
methods are provided to classify cancers
belonging to distinct diagnostic
categories, which often present
diagnostic dilemmas in clinical practice,
such as the small round blue cell tumors
(SRBCTs) of childhood, including
neuroblastoma (NB),
rhabdomyosarcoma RMS), Burkitt’s
lymphoma (BL), and the Ewing family
of tumors (EWS). More specifically, the
invention is an application of Artificial
Neural Networks (ANNs) for the
diagnostic classification of cancers
based on gene expression profiling data
Government-Owned Inventions;
Availability for Licensing
VerDate jul<14>2003
18:12 Feb 07, 2005
Jkt 205001
Dated: February 1, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–2366 Filed 2–7–05; 8:45 am]
BILLING CODE 4140–01–U
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: (301)
496–7057; fax: (301) 402–0220. A signed
Confidential Disclosure Agreement will
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
be required to receive copies of the
patent applications.
Methods for Prophylaxis and Treatment
of HER–2/neu Tumors
John C Morris, Jay A. Berzofsky, Yoshio
Sakai, Jong-Myun Park, Masake
Terabe (all of NCI).
Serial Nos. PCT/US2003/034362 filed
29 Oct 2003 (DHHS Reference No. E–
025–2003/1–PCT–1) and 60/422,395
filed 30 Oct 2002 (DHHS Reference
No. E–025–2003/0–US–01).
Licensing Contact: Susan S. Rucker;
(301) 435–4478;
ruckersu@mail.nih.gov.
This application relates to methods
for cancer prophylaxis and treatment.
More particularly, the application
relates to methods for the treatment and
prophylaxis of cancers caused by the
activity of the HER–2/neu/erbB–2 gene
employing immunotherapy. Such
cancers include breast cancers, cancers
of the female genital tract and some
cancers of the gastrointestinal tract.
The methods claimed involve the use
of a HER–2/neu vaccine employing
recombinant non-replicating adenovirus
expressing a HER–2/neu/erbB–2 gene.
In a preferred embodiment the vaccine
comprises a recombinant nonreplicating adenoviral vector encoding a
HER–2/neu/erbB–2 gene that is
expressed as a truncated HER–2/neu/
erbB–2 protein. Antigen presenting
cells, such as dendritic cells infected
with the recombinant adenoviral vector,
process and present the truncated HER–
2/neu/erbB–2 protein, thereby
stimulating an immune response.
Preferred HER–2/neu/erbB–2 proteins
contain regions of the extracellular
domain and the transmembrane domain
of the intact HER–2/neu/erbB–2 gene
product and do not contain any tyrosine
kinase domains.
This work has been published in part
in Sakai, Y, et al. Cancer Research
64(21): 8022 (Nov 1 2004) and as WO
2004/041065 (May 21 2004).
Antibodies and Polypeptides to AAMP–
1 for Use in Diagnosis and Therapy of
AAMP–1–Expressing Cancers
Lance Liotta et al. (NCI).
U.S. Patent No. 6,274,134 issued 14 Aug
2001 (DHHS Reference No. E–084–
1991/1–US–01); Australian Patent No.
684806 issued 23 Apr 1998 (DHHS
Reference No. E–084–1991/1–AU–05).
Licensing Contact: Thomas Clouse; (301)
435–4076; clousetp@mail.nih.gov.
Angio-associated migratory cell
protein (AAMP–1) was first isolated
from a human melanoma cell line as a
motility-associated cell protein. AAMP–
1 contains two immunoglobin domains,
E:\FR\FM\08FEN1.SGM
08FEN1
]]>Agencies
[Federal Register Volume 70, Number 25 (Tuesday, February 8, 2005)]
[Notices]
[Pages 6705-6706]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-2366]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Monoclonal Antibody 90.12 Recognizes a Novel B Cell Surface Antigen
Upregulated on Both Activated and Apoptotic Lymphocytes
Marjorie A. Shapiro et al. (FDA).
DHHS Reference No. E-195-2004/0--Research Tool.
Licensing Contact: Cristina Thalhammer-Reyero; 301/435-4507;
thalhamc@mail.nih.gov.
Monoclonal antibody 90.12 recognizes a molecule expressed on the
surface of a subset of B lymphocytes and on all types of blood cells.
This antigen is increased upon stimulation of B and T lymphocytes as
well as on cells undergoing programmed cell death. Amino acid
sequencing of the beginning of the protein suggests that it is a member
of the S100 family of calcium binding proteins. The antibody is further
described in ``Characterization of a B cell surface antigen with
homology to the S100 protein MRP8'' by Shapiro MA, Fitzsimmons SP,
Clark KJ, Biochem Biophys Res Commun. 1999 Sep 16;263(1):17-22 and ``A
novel activation induced lymphocyte surface antigen, 90.12, is also
expressed on apoptotic cells'' by Clark KJ, Monser M, Stein KE, Shapiro
MA, Scand J Immunol. 2000 Feb;51(2):155-63.
Methods for Analyzing High Dimensional Data for Classifying,
Diagnosing, Prognosticating, and/or Predicting Diseases and Other
Biological States
Javed Khan and Paul S. Meltzer (NHGRI), et al.
U.S. Patent Application No. 10/133,937 filed 25 Apr 2002 (DHHS
Reference No. E-324-2001/0-US-01).
Licensing Contact: Cristina Thalhammer-Reyero; 301/435-4507;
thalhamc@mail.nih.gov.
This invention relates to a method of using supervised pattern
recognition methods to classifying, diagnosing, predicting, or
prognosticating various diseases. The method includes
[[Page 6706]]
obtaining high dimensional experimental data, such as gene expression
profiling data, filtering the data, reducing the dimensionality of the
data through use of one or more methods, training a supervised pattern
recognition method, ranking individual data points from the data,
choosing multiple data points from the data based on the relative
ranking, and using the multiple data points to determine if an unknown
set of experimental data indicates a diseased condition, a predilection
for a diseased condition, or a prognosis about a diseased condition.
Artificial neural networks (ANNs) are computer-based algorithms
capable of pattern recognition particularly suited to making diagnoses.
ANNs do not require explicit encoding of process knowledge in a set of
rules and can be trained from examples to recognize and categorize
complex patterns. ANNs learn more efficiently when the data to be input
into the neural network is preprocessed. Various ANN approaches to the
analysis of data have seen extensive application to biomedical
problems, including those in the areas of diagnosis and drug
development. Unsupervised neural networks are also extensively used for
the analysis of DNA microarray data.
The technology is further described in J. Khan et al.,
``Classification and diagnostic prediction of cancers using gene
expression profiling and artificial neural networks,'' Nature Medicine,
7(6):673-679, June 2001.
Selections of Genes
Javed Khan and Paul S. Meltzer (NHGRI), et al.
U.S. Patent Application No. 10/159,563 filed 31 May 2002 (DHHS
Reference No. E-324-2001/1-US-01).
Licensing Contact: Cristina Thalhammer-Reyero; 301/435-4507;
thalhamc@mail.nih.gov.
The invention provides selections of genes expressed in a cancer
cell that function to characterize such cancer, and methods of using
the same for diagnosis and for targeting the therapy of selected
cancers. In particular, methods are provided to classify cancers
belonging to distinct diagnostic categories, which often present
diagnostic dilemmas in clinical practice, such as the small round blue
cell tumors (SRBCTs) of childhood, including neuroblastoma (NB),
rhabdomyosarcoma RMS), Burkitt's lymphoma (BL), and the Ewing family of
tumors (EWS). More specifically, the invention is an application of
Artificial Neural Networks (ANNs) for the diagnostic classification of
cancers based on gene expression profiling data derived from cDNA
microarrays. The ANNs were trained using as models. The ANNs then
correctly classified all samples tested and identified the genes most
relevant to the classification. Their study demonstrated the potential
applications of these methods for tumor diagnosis and for the
identification of candidate targets for therapy. The uniqueness of this
method is taking gene expression data generated by microarrays,
minimizing the genes from the original 1000s to less than 100,
identifying which genes are the most relevant to a classification,
which gives an immediate clue to the actual biological processes
involved, not just surrogate markers which have no bearing on the
biology.
The technology is further described in J. Khan et al.,
``Classification and diagnostic prediction of cancers using gene
expression profiling and artificial neural networks,'' Nature Medicine
7(6): 673-679, June 2001.
Dated: February 1, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-2366 Filed 2-7-05; 8:45 am]
BILLING CODE 4140-01-U
